SCHEMBL434045

SCHEMBL434045

Cc1noc(C)c1C(CC(=O)O)c1ccc(O)cc1

nearest known ligand 0.45

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
GAA P10253 4/20 0.45
ALDH1A1 P00352 3/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
NPY2R P49146 1/20 0.39
KDM4E B2RXH2 1/20 0.39
MAPT P10636 1/20 0.39
AGTR1 P30556 1/20 0.39
CTSA P10619 2/20 0.37
BRD4 O60885 5/20 0.36
CREBBP Q92793 2/20 0.35
CYP2C9 P11712 2/20 0.35
CYP2C19 P33261 2/20 0.35
CYP2D6 P10635 1/20 0.35
TAS2R8 Q9NYW2 1/20 0.35
KMT2A Q03164 2/20 0.35
MEN1 O00255 1/20 0.35
CYP3A4 P08684 1/20 0.34
ATM Q13315 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL433532 0.87 ALDH1A1 (0.41) GAAALDH1A1L3MBTL1NPY2RKDM4E
SCHEMBL2285716 0.74 CA2 (0.48) GAAALDH1A1MAPTCYP2C9CYP2C19
SCHEMBL22668333 0.74 FFAR1 (0.44) GAAL3MBTL1MAPT
Acetic Acid SCHEMBL11105301 0.72 ESR1 (0.47) GAAALDH1A1L3MBTL1MAPTCYP2C9
Propionic Acid SCHEMBL11105024 0.71 ESR1 (0.47) MAPTCYP2C9CYP2C19CYP2D6KMT2A
SCHEMBL3658988 0.69 CNR1 (0.51) GAAALDH1A1CYP2C19KMT2A
SCHEMBL14273258 0.69 FFAR1 (0.47) GAAALDH1A1KDM4ECYP2C9CYP2C19
SCHEMBL434752 0.69 FFAR1 (0.47) GAAALDH1A1KDM4ECYP2C9CYP2C19
SCHEMBL3521795 0.69 CTSA (0.40) CTSA
SCHEMBL3547610 0.68 FFAR1 (0.39) GAAALDH1A1CTSACYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2595952-B1 AGONISTS OF GPR40 CONNEXIOS LIFE SCIENCES PVT LTD (IN) 2020-11-18 EP disclosed
US-9278915-B2 Agonists of GPR40 CONNEXIOS LIFE SCIENCES PVT LTD (IN) 2016-03-08 US disclosed
US-9278915-B2 Agonists of GPR40 CONNEXIOS LIFE SCIENCES PVT LTD (IN) 2016-03-08 US disclosed
US-9278915-B2 Agonists of GPR40 CONNEXIOS LIFE SCIENCES PVT LTD (IN) 2016-03-08 US disclosed
US-20130237571-A1 AGONISTS OF GPR40 Conexios Life Sciences PVT. LTD. (IN) 2013-09-12 US disclosed
US-20130237571-A1 AGONISTS OF GPR40 Conexios Life Sciences PVT. LTD. (IN) 2013-09-12 US disclosed
US-20130237571-A1 AGONISTS OF GPR40 Conexios Life Sciences PVT. LTD. (IN) 2013-09-12 US disclosed
CN-103228622-A Agonists of gpr40 CONNEXIOS LIFE SCIENCES PVT LTD 2013-07-31 CN disclosed
EP-2595952-A1 AGONISTS OF GPR40 Connexios Life Sciences Pvt. Ltd. (IN) 2013-05-29 EP disclosed
WO-2012011125-A1 AGONISTS OF GPR40 CONNEXIOS LIFE SCIENCES PVT. LTD. (IN) 2012-01-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130237571-A1 AGONISTS OF GPR40 GPR65, GPR55, GPR68 GAA 1970/4885ALDH1A1 2410/4885L3MBTL1 4507/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.